

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

The University
of Michigan
Pharmacy
Library

CUMULATIVE SUPPLEMENT 11

AUG'83 - JUL'84

APPROVED PRESCRIPTION DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

SERIAL

REFERENCE

OCT 05 1984

PHARMACY
LIBRARY

REFERENCE
DATE

UNIVERSITY OF MICHIGAN
LIBRARIES

SEP 19 1984

DEPOSITED BY THE
UNITED STATES OF AMERICA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUGS AND BIOLOGICS

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN



Digitized by **Google**

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD< to the left of the line on which new information exists. The >ADD< symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLI> (DELETE) to the left of the line containing the overstruck print. The >DLI> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48 FR 45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled-released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
PROFESSIONAL PHARMACAL DIV STERI-MED INC	OPTOPICS LABORATORIES CORP	OPTOPICS LABS
MPL INC SOLOPAK DIV	SOLOPAK LABORATORIES	SOLOPAK LABORATORIES

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the APDP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

E. PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the Drug Product List.

<u>Drugs Containing</u>	<u>Federal Register Reference</u>
dicyclomine hydrochloride	JUN 22, 1984 (49 FR 25681)
nanrolone decanoate	JUL 15, 1983 (48 FR 32395)
neomycin sulfate with either: dexamethasone sodium phosphate, fluocinolone acetonide, flurandrenolide, hydrocortisone, or methylprednisolone acetate. [topical anti-infectives for dermatologic use]	MAR 26, 1984 (49 FR 11888)
neomycin sulfate, polymyxin B sulfate, bacitracin zinc, and hydrocortisone [topical ointment]	MAY 4, 1984 (49 FR 19147)
phenazopyridine hydrochloride and sulfamethoxazole	JUL 29, 1983 (48 FR 34516)
sulfanilamide and aminacrine tranylcypromine sulfate	AUG 22, 1983 (48 FR 38097) MAR 22, 1984 (49 FR 10708)

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '83 (BASELINE)	OCT '83	JAN '84	APR '84
DRUG PRODUCTS LISTED	6679	6783	6854	6938
SINGLE SOURCE	1908 (28.6%)	1915 (28.2%)	1933 (28.2%)	1940 (28.0%)
MULTISOURCE (1)	4771 (71.4%)	4868 (71.8%)	4921 (71.5%)	4998 (72.0%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)	3839 (57.5%)	4014 (57.9%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)	972 (14.8%)	974 (14.0%)
EXCEPTIONS (2)	10 (0.1%)	10 (0.1%)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	304	310	312	313
NUMBER OF APPLICANTS	-	2	8	9

B. ACTIVITY FOR SUPPLEMENT NUMBER 11

	MAY '84	JUN '84	JUL '84	CUMULATIVE
DRUG PRODUCTS ADDED:	52	39	47	138
NEWLY APPROVED	52	38	42	132
DESIGN EFFECTIVE	0	1	5	6
REMARKETED	0	0	0	0
DRUG PRODUCTS REMOVED:	14	3	7	24
WITHDRAWN APPROVAL	0	0	0	0
RX TO OTC SWITCH	0	0	0	0
DISCONTINUED MARKETING	14	3	7	24
NET GAIN IN DRUG PRODUCTS	38	36	40	114
SINGLE SOURCE PRODUCTS APPROVED	18	6	16	40
MULTISOURCE DRUG PRODUCTS APPROVED	34	33	31	98
NEW MOLECULAR ENTITIES APPROVED:	5	0	2	7
AS THE ENTITY	3	0	1	4
AS A SALT, ESTER OR DERIVATIVE	2	0	1	3
OF THE ENTITY				
(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.E., AVAILABLE FROM MORE THAN ONE APPLICANT)				
(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)				

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL
ACETAMINOPHEN W/ CODEINE #2
 AA LEHMON 300MG;15MG*
ACETAMINOPHEN W/ CODEINE #3
 AA LEHMON 300MG;30MG*
ACETAMINOPHEN W/ CODEINE #4
 AA LEHMON 300MG;60MG*
TYLENOL W/ CODEINE NO. 3
 AA MCNEIL PHARM 300MG;30MG
TYLENOL W/ CODEINE NO. 4
 AA MCNEIL PHARM 300MG;60MG

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
 AA DURAMED PHARMS 300MG;15MG*
 AA 300MG;30MG*
 AA 300MG;60MG*
PAPA-DEINE #3
 AA VANGARD LABS/MSM 300MG;30MG*
PAPA-DEINE #4
 AA VANGARD LABS/MSM 300MG;60MG*

ACETAMINOPHEN; HYDROCODONE BITARTRATE (PAGE 3-2)

TABLET; ORAL
HYCODAPHEN
 AA BF ASCHER 500MG;5MG

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL
ODACET
 AA HALSEY DRUG 325MG;5MG*
PERCODET-5/
PERCODET

/ACETAMINOPHEN; METHADONE; PHENYLPROPANOLAMINE HYDROCHLORIDE;/
PHENYLTOLOXAMINE CITRATE/ (PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, IODINATED, I-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION
RADIOIODINATED SERUM ALBUMIN (HUMAN) INSA I-131/
/HALL INCKRODT/ (6.7-250 UCL/ML)

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION
 AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTIDINE
 CUTTER-VITRUM 5.2%*
 AMINOSYN 3.5% IN PLASTIC CONTAINER
 ABBOTT LABORATORIES 3.5%*
 NEOPHAM 6.5%
 CUTTER-VITRUM 6.5%*
 TROPHAMINE 6%
 AM MCBAH/AM HOSP 6%*

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE (PAGE 3-7)

INJECTABLE; INJECTION
 AMINOSYN 3.5% M IN PLASTIC CONTAINER
 ABBOTT LABORATORIES 3.5%;21MG/100ML;40MG/100ML;
 128MG/100ML;234MG/100ML*

AMINOPHYLLINE (PAGE 3-8)

/Aminophylline Oral/
 SOLUTION; ORAL
AMINOPHYLLINE
 AA BAY LABORATORIES 105MG/5ML*
 AA ROXANE LABORATORIES 105MG/5ML*

TABLET; ORAL
AMINOPHYLLINE
 BD BARR LABORATORIES 100MG*
 BD 200MG*
 AB VANGARD LABS/MSM 100MG*
 AB 200MG*

AMITRIPTYLINE HYDROCHLORIDE (PAGE 3-9)

TABLET; ORAL
AMITRIPTYLINE HCL
 AB DANBURY PHARMACAL 10MG*
 AB 25MG*
 AB 50MG*
 AB 75MG*
 AB 100MG*
 AB 150MG*
 BP COPLEY PHARM 10MG*
 BP 25MG*
 BP 50MG*
 BP 75MG*
 BP 100MG*
 BP 150MG*

AB BUTALBUTAL AND CAFFEINE N/ BUTALBUTAL 325MG:50MG:140MGX
AB PURPAC/KALIPHARM 325MG:50MG:140MGX
AB BUTAL COMPOUND 325MG:50MG:140MGX
AB CORD LABORATORIES 325MG:50MG:140MGX
AB BUTALBUTAL N/ ASPERIN AND CAFFEINE 325MG:50MG:140MGX
AB CHELSEA LABORATORIES 325MG:50MG:140MGX
AB BUTALBUTAL N/ ASPERIN & CAFFEINE 325MG:50MG:140MGX
AB BOOTS LABORATORIES 325MG:50MG:140MGX

ASPIRIN: BUTALBUTAL: CAFFEINE (PAGE 3-15)

TABLET: ORAL
AXOTAL
ADRIA LABORATORIES 650MG:50MGX

ASPIRIN: BUTALBUTAL (PAGE 3-15)

> ADD > AMYKONE LACTATE (PAGE 3-15)
> ADD > INJECTABLE: INJECTION
> ADD > INOCOR
> ADD > MINIHROP LABS/STERL EQ 5MG BASE/MLX

AB BIOCRAFT LABS EQ 5-BGM BASE/BOI:16M/BOI
AB PROGRAMPACIN EQ 5-BGM BASE/BOI:16M/BOI
AB BRISTOL LABS/B-M
AB POLYGLYIN-PBS
POWDER FOR RECONSTITUTION: ORAL
AMPCILLIN TRIHYDRATE: PROBENECID (PAGE 3-13)

/CAPSULE: CONTROLLED RELEASE: ORAL
/BENZERINE/
/SKAT. LABORATORIES/ 15MG/
/TABLET: ORAL/
/BENZERINE/
/SKAT. LABORATORIES/ 15MG/
/SKAT. LABORATORIES/ 15MG/
/10MG/

AB INJECTABLE: INJECTION
AB AMMONIUM CHLORIDE
AB AMMONIUM CHLORIDE IN PLASTIC CONTAINER
AB AMMONIUM CHLORIDE 5MG/ML
AB AMMONIUM CHLORIDE 5MG/ML
AB AMMONIUM CHLORIDE 5MG/ML
AB AMMONIUM CHLORIDE 5MG/ML

AMMONIUM CHLORIDE (PAGE 3-11)
DRUG-PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 11 - JULY 64
Original from
UNIVERSITY OF MICHIGAN

TABLET: ORAL
VICOPRIN
KNOLL PHARMACEUTICAL 500MG:5MGX

ASPIRIN: HYDROCODONE BITARTRATE (PAGE 3-16)

TABLET: ORAL
SOMA COMPOUND M/ CODEINE
MALLACE PHARMS/C-M 325MG:200MG:16MGX

ASPIRIN: CARISOPRODOL: CODEINE PHOSPHATE (PAGE 3-16)

TABLET: ORAL
SOMA COMPOUND
MALLACE PHARMS/C-M 325MG:200MGX

ASPIRIN: CARISOPRODOL (PAGE 3-16)

AA DARVON COMPOUND-65
AA ELI LILLY INDSTRS/PR 325MG:32.4MG:65MG
AA PROPOXYPHENE COMPOUND 65
AA LEMON
AA SK-65 COMPOUND
AA SKAT. LABORATORIES 325MG:32.4MG:65MGX

ASPIRIN: CAFFEINE: PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN: CAFFEINE: PHENACETIN: PROPOXYPHENE HYDROCHLORIDE/
(PAGE 3-15)

CAPSULE: ORAL
SYNLABS-DC
IVES LABS/AMHO 356.4MG:30MG:16MGX

ASPIRIN: CAFFEINE: DIHYDROCODEINE BITARTRATE (PAGE 3-15)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN: BUTALBUTAL: CAFFEINE: PHENACETIN (PAGE 3-15)

ASPIRIN; MEPROBAMATE (PAGE 3-16)

TABLET; ORAL
EQUASESIC
 AB WYETH LABS/AMHO 325MG;200MG
MEPROGESIC Q
 AB QUANTUM PHARMICS 325MG;200MG
MICRAININ
 AB WALLACE PHARMS/C-M 325MG;200MG

ATENOLOL; CHLORTHALIDONE (PAGE 3-16)

TABLET; ORAL
 TENORETIC 100
 STUART PHARMS/ICI AM 100MG;25MG
 TENORETIC 50
 STUART PHARMS/ICI AM 50MG;25MG

ATRACURIUM BESYLATE (PAGE 3-16)

INJECTABLE; INJECTION
 TRACRIUM
 BURROUGHS WELLCOME 10MG/ML

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE (PAGE 3-17)

LIQUID; ORAL
/LONDOLATE/
 /AA/ /CORP. LABORATORIES/ /0.025MG/5ML; 0.1MG/5ML/

/AZURETIN/ (PAGE 3-18)

/GRANULES; ORAL/
 /DIAGNEX BLUE/
 /ER. SQUIBB AND SONS/ /25V/PACKET/

BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
 SPECTROBID
 PFIZER LABS/PFIZER 800MG

BACITRACIN (PAGE 3-18)

ointment; OPHTHALMIC
BACITRACIN
 AT PHARMAFAIR 500 UNITS/GM

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-18)

ointment; OPHTHALMIC
CORTISPORIN
 AT BURROUGHS WELLCOME 400 UNITS/GM;12;EQ 3.5GM BASE/GM;
 10,000 UNITS/GM
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE &
HYDROCORTISONE
 /PHARMAFAIR/ /400 UNITS/GM;12;EQ 3.5GM BASE/GM;
 /5,000 UNITS/GM/
 AT PHARMAFAIR 400 UNITS/GM;12;EQ 3.5GM BASE/GM;
 10,000 UNITS/GM

BENTITROMIDE (PAGE 3-19)

SOLUTION; ORAL
 CHYMEX
 ADRIA LABORATORIES 500MG/7.5ML

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL
 AQUATAG
 /BP/ /CORP. LABORATORIES/ /50MG/
 /25MG/
 BP REID-PROVIDENT LABS 50MG
 25MG
 /BP/ /PROLOG/ /50MG/
 /BP/ /REID-PROVIDENT LABS/ /50MG/

BENZTROPINE MESYLATE (PAGE 3-20)

TABLET; ORAL
 BENZTROPINE MESYLATE
 BP QUANTUM PHARMICS 0.5MG
 BP 1MG
 BP 2MG
 COGENTIN
 BP MSD/MERCK 0.5MG
 BP 1MG
 BP 2MG

BETAMETHASONE DIPROPIONATE (PAGE 3-21)

CREAM; TOPICAL
ALPHATREX
 AB SAVAGE LABS/BYK-GLDN EQ 0.05% BASE
BETAMETHASONE DIPROPIONATE
 AB E FOUGERA/BYK-GLDN EQ 0.05% BASE
 AB PHARMADERM/BYK-GLDN EQ 0.05% BASE
DIPROSONE
 AB SCHERING EQ 0.05% BASE

BUTABARBITAL SODIUM (PAGE 3-24)

ELIXIR; ORAL
 /AA/ /BUTABARBITAL SODIUM/ /33MG/5ML/
 /NEST-HARD/
 BUTALAN
 /AA/ /LANNETT/ /33.3MG/5ML/
 LANNETT 33.3MG/5ML

CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE; PHENACETIN
(PAGE 3-24)

/TABLET; ORAL/
 /SOMA COMPOUND W/ CODEINE/
 /WALLACE PHARMS/E-W/ /32MG;200MG;16MG;160MG/

CAFFEINE; CARISOPRODOL; PHENACETIN (PAGE 3-25)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

CAFFEINE; ERGOTAMINE TARTRATE (PAGE 3-25)

SUPPOSITORY; RECTAL
 CAFERGOT
 BR SANDOZ PHARMS/SANDOZ 100MG;2MG
 MIGRAINE
 BR ORGANON/AKZONA 100MG;2MG

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
 DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER
 AM MCGAM/AM HOSP 510MG/100ML;30GM/100ML;
 200MG/100ML;9.2GM/100ML;
 9.6GM/100ML
 510MG/100ML;30GM/100ML;
 200MG/100ML;9.4GM/100ML;
 11GM/100ML
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER
 AM MCGAM/AM HOSP 510MG/100ML;50GM/100ML
 200MG/100ML;9.2GM/100ML;
 9.6GM/100ML
 510MG/100ML;50GM/100ML;
 200MG/100ML;9.4GM/100ML;
 11GM/100ML

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
 DIALYTE W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
 AM MCGAM/AM HOSP 26MG/100ML;2.5GM/100ML;
 15MG/100ML;560MG/100ML;390MG/100ML

> ADD > CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;
 > ADD > SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-27)

> ADD > INJECTABLE; INJECTION
 > ADD > TPN ELECTROLYTES IN PLASTIC CONTAINER
 > ADD > ABBOTT LABORATORIES 16.5MG/ML;25.4MG/ML;74.6MG/ML;
 > ADD > 121MG/ML;16.1MG/ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE (PAGE 3-27)

INJECTABLE; INJECTION
 ISOLYTE E IN PLASTIC CONTAINER
 AM MCGAM/AM HOSP 35MG/100ML;30MG/100ML;
 74MG/100ML;640MG/100ML;
 500MG/100ML;74MG/100ML

CEFONICID SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
 MONOCID
 SK&F LABORATORIES EQ 500MG BASE/VIALM
 EQ 1GM BASE/VIALM
 EQ 2GM BASE/VIALM
 EQ 10GM BASE/VIALM

CEFORANIDE (PAGE 3-30)

INJECTABLE; INJECTION
 PRECEF
 BRISTOL LABS/B-M 500MG/VIALM
 1GM/VIALM
 2GM/VIALM
 10GM/VIALM
 20GM/VIALM

CEFTIZOXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
 CEFIZOX
 SK&F LABORATORIES EQ 1GM BASE/VIALM
 EQ 2GM BASE/VIALM

CHLORPROPAMIDE (PAGE 3-38)

TABLET; ORAL
CHLORPROPAMIDE
 AB BOLAR PHARMACEUTICAL 100MG
 AB 250MG
 AB MYLAN PHARMS 100MG
 AB 250MG
 AB PAR PHARMACEUTICAL 100MG
 AB 250MG
DIABTNESE
 AB PFIZER LABS/PFIZER 100MG

CHLORTHALIDONE (PAGE 3-38)

TABLET; ORAL
CHLORTHALIDONE
 AB PUREPAC/KALIPHARMA 50MG

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE (PAGE 3-39)

TABLET; ORAL
 COMBIPRES
 BOEHRINGER INGELHEIM 15MG;0.3MG

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL
CHLORZOXAZONE
 AA PAR PHARMACEUTICAL 250MG

CHYMOPAPAIN (PAGE 3-39)

INJECTABLE; INJECTION
 DISCAGE
 TRAVENOL LABS 12,500 UNITS/VIALX

CHTETIDINE (PAGE 3-39)

TABLET; ORAL
 TAGAMET
 SK&F LAB 400MG

CLOTRIMAZOLE (PAGE 3-41)

LOTION; TOPICAL
 LOTRIMIN
 SCHERING 12X

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-42)

SYRUP; ORAL
 PHENERGAN VC W/ CODEINE
 WYETH LABS/AMHO 10MG/5ML;5MG/5ML;6.25MG/5ML

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-42)

SYRUP; ORAL
 PHENERGAN W/ CODEINE
 WYETH LABS/AMHO 10MG/5ML;6.25MG/5ML

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-42)

SYRUP; ORAL
 ACTIFED W/ CODEINE
 BURROUGHS WELLCOME 10MG/5ML;30MG/5ML;1.25MG/5ML

CORTICOTROPIN (PAGE 3-43)

INJECTABLE; INJECTION
 /REPOSITORY CORTICOTROPIN/
 /BC/ WYETH LABS/AMHO /40 UNITS/ML/
 /BC/ /40 UNITS/ML/

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
CYANOCOBALAMIN
 AP SOLOPAK/MPL 1MG/ML
DODECAMIN
 AP MAURRY BIOLOGICAL 1MG/ML
 /AP/ REDISOL /6.1MG/ML/
 /AP/ MS&D/MERCK /6.1MG/ML/
 /AP/ SYTOBEX /6.1MG/ML/
 /AP/ PARKE DAVIS/M-L /6.1MG/ML/

TABLET; ORAL
 /REDISOL/
 /MS&D/MERCK/ /6.5MG/

CYCLOSPORINE (PAGE 3-46)

INJECTABLE; INJECTION
 SANDIMMUNE
 SANDOZ PHARMS/SANDOZ 50MG/ML
 SOLUTION; ORAL
 SANDIMMUNE
 SANDOZ PHARMS/SANDOZ 100MG/ML

Original from

UNIVERSITY OF MICHIGAN

DEXTROSE; HEPARIN SODIUM (PAGE 3-53)

INJECTABLE; INJECTION
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
TRAVENOL LABS 5GM/100ML; 4,000 UNITS/100ML

DEXTROSE; LIDOCAINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 5GM/100ML; 200MG/100ML
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 5GM/100ML; 400MG/100ML
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 5GM/100ML; 800MG/100ML

DIATRIZOATE MEGALUMINE; DIATRIZOATE SODIUM (PAGE 3-57)

INJECTABLE; INJECTION
/DIATRIZOATE MEGALUMINE AND DIATRIZOATE SODIUM/
DIATRIZOATE-60

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

TABLET; ORAL
DIETHYLPROPION HCL
AA CAMALL 25MG

DIMENHYDRINATE (PAGE 3-60)

INJECTABLE; INJECTION
DIMENHYDRINATE
/AA/ /INTL MEDICATION SYS/ /20MG/ML/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
AA HALSEY DRUG 50MG
/AA/ SK-DIPHENHYDRAMINE
/AA/ SK&F LABORATORIES /25MG/

ELIXIR; ORAL
BELTX
AA HALSEY DRUG 12.5MG/5ML
DIBENTL
AA HR CENCI LABS 12.5MG/5ML
/AA/ DIPHENHYDRAMINE HCL
/AA/ /CORD LABORATORIES/ /12.5MG/5ML/
/AA/ SK-DIPHENHYDRAMINE
/AA/ /SK&F LABORATORIES/ /12.5MG/5ML/

DISULFIRAM (PAGE 3-63)

TABLET; ORAL
DISULFIRAM
BX CHELSEA LABORATORIES 250MG
BX 500MG
BX SIDMAK LABORATORIES 250MG
BX 500MG

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL
DOXY-LEMMON
AB LEMMON EQ 100MG BASE
DOXYCYCLINE HYCLATE
AB CHELSEA LABORATORIES EQ 50MG BASE
AB HEATHER DRUG EQ 50MG BASE
AB EQ 100MG BASE
/AB/ /LEMMON/ /EQ 100MG BASE/
AB DRUMMER/PHOENIX EQ 100MG BASE
AB PAR PHARMACEUTICAL EQ 100MG BASE
AB PUREPAC/KALIPHARMA EQ 50MG BASE
AB EQ 100MG BASE
AB WEST-WARD EQ 100MG BASE

INJECTABLE; INJECTION
DOXY 100
AP LYPHO-MED EQ 100MG BASE/VIAL
DOXY 200
AP LYPHO-MED EQ 200MG BASE/VIAL
DOXYCYCLINE
AP ELKINS-SINN EQ 100MG BASE/VIAL
AP EQ 200MG BASE/VIAL
VIBRANHYCIN
AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

TABLET; ORAL
DOXYCYCLINE HYCLATE
AB HEATHER DRUG EQ 100MG BASE

> DLT > DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE (PAGE 3-64)

> DLT > /TABLET; CONTROLLED RELEASE; ORAL/
> DLT > /BENDECTIN/
> DLT > /MERRELL DOX/DOX CHEN/10MG; 10MG/

PROPERIDOL; FENTANYL CITRATE (PAGE 3-64)

INJECTABLE; INJECTION
INNOVAR
/JANSSEN PHARMA/ /2.5MG/ML; 0.05MG/ML/
JANSSEN PHARMA 2.5MG/ML; EQ 0.05MG BASE/ML

AA : PARKE-DAVIS/M-L
2MG

ERGOTAMINE TARTRATE (PAGE 3-67)

AB : CHELSEA LABORATORIES 1MG
ERGOLOID MESYLATES

CAPSULE: ORAL
HYDERGINE LC

ERGOLOID MESYLATES (PAGE 3-66)

AP : PHARMATON/52
0.02MG/ML; 22M
LIDOCAINE
INJECTABLE: INJECTION

EPINEPHRINE: LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

AYERST LABS/AMHO

0.03%
0.06%
0.125%
0.25%

PHOSPHOLINE IODIDE

0.25%
0.125%
0.06%
0.03%

POWDER FOR RECONSTITUTION: OPHTHALMIC

ECHTHIOPHATE IODIDE (PAGE 3-65)

ASTRA PHARM PRODS

1X
0.5%
1X
1X

DICLONE

SOLUTION: TOPICAL

DICLONINE HYDROCHLORIDE (PAGE 3-64)

BRISTOL LABS/B-M
VEPESIO
INJECTABLE: INJECTION
ETIOPESIO (PAGE 3-74)

0.035MG; 0.5MG AND 1MG

0.035MG; 0.5MG, 0.75MG AND 1MG

0.035MG; 0.5MG AND 1MG

0.035MG; 0.5MG AND 1MG

0.035MG; 0.5MG, 0.75MG AND 1MG

0.035MG; 0.5MG AND 1MG

0.035MG; 0.5MG AND 1MG

ETHINYL ESTADIOL: NORTETHINDRONE (PAGE 3-72)

AYERST LABS/AMHO

0.9MG

ESTROGENS, CONJUGATED (PAGE 3-70)

0.01%
ESTRACE
HEAD JOHNSON/B-M

CREAM: VAGINAL

ESTRADIOL (PAGE 3-69)

3.5MG

SOLUTION: TOPICAL

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

ERYTHROMYCIN

FENTANYL CITRATE (PAGE 3-75)

INJECTABLE; INJECTION
FENTANYL
 >_ADD_> AP ELKINS-SINN/AHROBINS EQ 0.05MG BASE/ML
SUBLITMAZE
 >_ADD_> AP JANSSEN PHARMA /0.05MG/ML/
 JANSSEN PHARMA EQ 0.05MG BASE/ML

FLUOCINOLONE ACETONIDE (PAGE 3-76)

CREAM; TOPICAL
FLUOCET
 AT NMC LABORATORIES 0.012M
 AT 0.0252M

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
 AT PHARMAFAIR 0.0252M

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
 AT BAY LABORATORIES 0.012M
 AT PHARMAFAIR 0.012M

>_ADD_> FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE (PAGE 3-76)

>_ADD_> CREAM; TOPICAL
 >_ADD_> NEO-SYNALAR
 >_ADD_> SYNTEX LABS/SYNTEX 0.025%;EQ 3.5MG BASE/GM

FLUOCINONIDE (PAGE 3-76)

CREAM; TOPICAL
LIDEX
 /AT/ /SYNTEX LABS/SYNTEX/ /0.052/
 AB SYNTEX LABS/SYNTEX 0.052
LIDEX-E
 /AT/ /SYNTEX LABS/SYNTEX/ /0.052/
 AB SYNTEX LABS/SYNTEX 0.052
VASODERM
 AB K-LINE PHARMS 0.052M

SOLUTION; TOPICAL
LIDEX
 SYNTEX LABS/SYNTEX 0.052M

FLUOXHYMESTERONE (PAGE 3-77)

TABLET; ORAL
FLUOXHYMESTERONE
 BP BOLAR PHARMACEUTICAL 2MG
 BP 5MG
 BP 10MG
 BP COLMED LABORATORIES 10MG

>_ADD_> FLURANDRENOLIDE; NEOMYCIN SULFATE (PAGE 3-78)

>_ADD_> CREAM; TOPICAL
 >_ADD_> CORDRAN-N
 >_ADD_> DISTA PRODS/LILLY 0.05%;EQ 3.5MG BASE/GM
 >_ADD_> OINTMENT; TOPICAL
 >_ADD_> CORDRAN-N
 >_ADD_> DISTA PRODS/LILLY 0.05%;EQ 3.5MG BASE/GM

FOLIC ACID (PAGE 3-78)

TABLET; ORAL
FOLIO ACID
 AA VANGARD LABS/1MM 1MG

FUROSEMIDE (PAGE 3-79)

INJECTABLE; INJECTION
FUROSEMIDE
 AP INVENEX LABS/DEXTER 10MG/ML
 AP NATCON 10MG/ML

TABLET; ORAL
FUROSEMIDE
 >_ADD_> AB BARR LABORATORIES 40MG
 >_ADD_> AB DRUMMER/PHOENIX 40MG
 >_ADD_> AB INTL MEDICATION SYS 20MG
 >_ADD_> AB 40MG
 >_ADD_> AB ROXANE LABORATORIES 20MG
 >_ADD_> AB 40MG
 >_ADD_> AB SUPERPHARM 20MG
 >_ADD_> AB ZENITH LABORATORIES 20MG
 >_ADD_> AB 40MG

GENTAMICIN SULFATE (PAGE 3-79)

CREAM; TOPICAL
GENTAFAIR
 AT PHARMAFAIR EQ 1MG BASE/GM
 >_ADD_> AT GENTAMICIN SULFATE
 >_ADD_> AT E FOUGERA/BYK-GLON EQ 1MG BASE/GM
 >_ADD_> AT NMC LABORATORIES EQ 1MG BASE/GM
 >_ADD_> AT PHARMADERM/BYK-GLON EQ 1MG BASE/GM

Digitized by Google

UNIVERSITY OF MICHIGAN

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-85)

INJECTABLE; INJECTION
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
 AP ABBOTT LABORATORIES 10,000 UNITS/100ML; 450MG/100ML
 HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%
 ABBOTT LABORATORIES 10,000 UNITS/100ML; 900MG/100ML
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45%
 AP ABBOTT LABORATORIES 5,000 UNITS/100ML; 450MG/100ML
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
 AP ABBOTT LABORATORIES 5,000 UNITS/100ML; 900MG/100ML
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%
 AP ABBOTT LABORATORIES 10,000 UNITS/100ML; 450MG/100ML
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%
 AP ABBOTT LABORATORIES 5,000 UNITS/100ML; 900MG/100ML
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%
 AP ABBOTT LABORATORIES 100 UNITS/ML; 4.5MG/ML

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL
HOMAPIN-10
 /AA/ MISSION PHARMACAL 10MG
 /SEUS-TENS SE/
 /AA/ /LEHMAN/ /10MG/

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

INJECTABLE; INJECTION
APRESOLINE
 AP CIBA/CIBA-GEIGY 20MG/ML
HYDRALAZINE HCL
 AP SOLOPAK LABORATORIES 20MG/ML

TABLET; ORAL
HYDRALAZINE HCL
 AA PAR PHARMACEUTICAL 100MG
 AA PUREPAC/KALIPHARMA 50MG
 AA QUANTUM PHARMICS 10MG
 AA 25MG
 AA 50MG
 AA 100MG
 AA SIDMAK LABORATORIES 25MG
 AA 50MG

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE (PAGE 3-87)

CAPSULE; ORAL
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25
 AB ZENITH LABORATORIES 25MG; 25MG
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50
 AB ZENITH LABORATORIES 50MG; 50MG
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50
 AB ZENITH LABORATORIES 100MG; 50MG

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-87)

TABLET; ORAL
/R-HCL-H/
 RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL
 RESERPINE, HYDRALAZINE HCL, AND HYDROCHLOROTHIAZIDE
 BP BARR LABORATORIES 25MG; 15MG; 0.1MG
 BP REID-PROVIDENT LABS 25MG; 15MG; 0.1MG

HYDROCHLOROTHIAZIDE (PAGE 3-88)

> ADD > SOLUTION; ORAL
 > ADD > HYDROCHLOROTHIAZIDE
 > ADD > ROXANE LABORATORIES 50MG/5ML
 > ADD > HYDROCHLOROTHIAZIDE INTENSOL
 > ADD > ROXANE LABORATORIES 100MG/ML

HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-89)

TABLET; ORAL
 RESERPINE AND HYDROCHLOROTHIAZIDE
 BP CORD LABORATORIES 50MG; 0.125MG
 RESERPINE AND HYDROCHLOROTHIAZIDE-50
 BP WEST-WARD 50MG; 0.125MG

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE (PAGE 3-89)

TABLET; ORAL
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
 AB PUREPAC/KALIPHARMA 25MG; 25MG

HYDROCORTISONE (PAGE 3-90)

CREAM; TOPICAL
ELDECORT
 /AI/ ELDER PHARMS /0.5%/
HYDROCORTISONE
 AT BAY LABORATORIES 1%
 AT 2.5%
FINECORT
 AT HERBERT LABS/ALLERGEN 1%
 AT 2.5%

UNIVERSITY OF MICHIGAN

HYDROCORTISONE VALERATE (PAGE 3-95)

ointment; topical
WESTCORT
NESTWOOD PHARMS 0.22%

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL
HYDROFLUMETHIAZIDE AND RESERPINE
BP COLMED LABORATORIES 50MG;0.125MG

HYDROMORPHONE HYDROCHLORIDE (PAGE 3-95)

INJECTABLE; INJECTION
DILAUDID-HP
KNOLL PHARMACEUTICAL 10MG/ML

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL
HYDROXYZINE HCL
AB BARR LABORATORIES 10MG
AB DANBURY PHARMACAL 10MG
AB 25MG
AB 50MG

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL
HYDROXYZINE PAMOATE
AB BARR LABORATORIES EQ 25MG HCL
AB EQ 50MG HCL
AB EQ 100MG HCL
AB DURAMED PHARMS EQ 25MG HCL
AB EQ 50MG HCL
AB EQ 100MG HCL
AB VANGARD LABS/PHM EQ 25MG HCL
AB EQ 50MG HCL

IBUPROFEN (PAGE 3-97)

TABLET; ORAL
MOTRIN
AB UPJOHN MANUFACTURING 600MG
AB RUFEN
AB BOOTS PHARMACEUTICAL 600MG

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
/BP/ /ANTIPRESS/ /25MG/
/BP/ /LEMON/ /25MG/
/AB/ /IMAVATE/ /25MG/
/AB/ /AM. ROBINS/ /50MG/
IMIPRAMINE HCL
AB GEIGY/CIBA-GEIGY 10MG
AB 25MG
AB 50MG
AB PAR PHARMACEUTICAL 10MG
AB 25MG
AB 50MG
TOFRANTIL
/BP/ /GEIGY/CIBA-GEIGY/ /25MG/
AB GEIGY/CIBA-GEIGY 25MG

INDOMETHACIN (PAGE 3-98)

CAPSULE; ORAL
INDOCIN
AB MSD/MERCK 25MG
AB 50MG
> ADD > AB CHELSEA LABORATORIES 25MG
> ADD > AB 50MG
AB LEDERLE LABS/AM CYAN 25MG
AB 50MG
AB MYLAN PHARMS 25MG
AB 50MG
AB ZENITH LABORATORIES 25MG
AB 50MG

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION
ISOETHARINE HCL
AN ARMOUR PHARM 0.167%
AN 0.22%
AN 0.28%
AN INTL MEDICATION SYS 0.167%
AN ROXANE LABORATORIES 0.167%
AN TRAVENOL LABS 0.14%
AN 0.25%

ISONIAZID (PAGE 3-101)

SYRUP; ORAL
ISONIAZID
AA CAROLINA MED PRODS 50MG/5ML
AA RIMIFON
AA HOFFMANN-LA ROCHE 50MG/5ML

MEPROBAMATE (PAGE 3-112)

TABLET; ORAL

> DLT > /AA/ Meproamate /BOLAR PHARMACEUTICAL/ 400MG/
 > DLT > /AA/ /MYLAN PHARMS/ 600MG/
 > DLT > /AA/ /MYLAN PHARMS/ 600MG/

METHAQUALONE (PAGE 3-116)

TABLET; ORAL

/500MG/
 /ANNAP. STONE/AM. HOSP/ 175MG/

METHOCARBAMOL (PAGE 3-117)

TABLET; ORAL

Methocarbamol
 AA ROXANE LABORATORIES 500MGH
 AA 750MGH

METHYLDOPA (PAGE 3-119)

TABLET; ORAL

Aldomet
 AB MSD/MERCK 250MG
 AB 500MG
Methyldopa
 AB CORD LABORATORIES 250MGH
 AB 500MGH

METHYLPREDNISOLONE (PAGE 3-120)

TABLET; ORAL

METHYLPREDNISOLONE
 BP DURAMED PHARMS 4MG

>_ADD> METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE (PAGE 3-120)

>_ADD> CREAM; TOPICAL
 >_ADD> NEO-MEDROL
 >_ADD> UPJOHN 0.25%;EQ 3.5MG BASE/GM
 >_ADD> 1%;EQ 3.5MG BASE/GM

METHYLPREDNISOLONE SODIUM SUCCINATE (PAGE 3-120)

INJECTABLE; INJECTION

Methylprednisolone Sodium Succinate
 >_ADD> AP CARTER-GLOGAU LABS EQ 500MG BASE/VIALH
 >_ADD> AP EQ 1GN BASE/VIALH
 AP LYPHOMED EQ 40MG BASE/VIALH
 AP EQ 125MG BASE/VIALH
 AP EQ 500MG BASE/VIALH
 AP EQ 1GN BASE/VIALH

METHYLTESTOSTERONE (PAGE 3-121)

TABLET; BUCCAL/SUBLINGUAL

METHYLTESTOSTERONE
 /BP/ /STONE. PAULSEN/ /10MG/

METOPROLOL TARTRATE (PAGE 3-122)

INJECTABLE; INJECTION

LOPRESSOR
 GEIGY/CIBA-GEIGY 1MG/MLH

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION

Metronidazole
 AP ABBOTT LABORATORIES 500MG/100MLH
 AP ELKINS-SINN/AHROBINS 500MG/100MLH
METRONIDAZOLE IN PLASTIC CONTAINER
 AP ABBOTT LABORATORIES 500MG/100MLH
METRO I.V. IN PLASTIC CONTAINER
 AP AM MCGAM/AM HOSP 500MG/100MLH

TABLET; ORAL

Metronidazole
 AB CHELSEA LABORATORIES 500MGH
 AB LMK INTERNATIONAL 250MGH
 AB PAR PHARMACEUTICAL 250MGH
 AB 500MGH

MANDROLONE DECANOATE (PAGE 3-125)

INJECTABLE; INJECTION

Mandrolone Decanoate
 AP CARTER-GLOGAU 200MG/MLH
 AP LEHMANN 100MG/ML
 50MG/ML
 AP LYPHOMED 100MG/MLH
 AP 200MG/MLH
 AP MAURRY BIOLOGICAL 100MG/MLH

Original from
UNIVERSITY OF MICHIGAN

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL

/AA/ /OXICAP/ /ED 250MG BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL

/AA/ /UTICILLIN VK/ /ED 125MG BASE/5ML/
/AA/ /UPJOHN/ /ED 250MG BASE/5ML/

PHENDIMETRAZINE TARTRATE (PAGE 3-138)

TABLET; ORAL

AA PHENDIMETRAZINE TARTRATE
FERNDAL LABS 35MG

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL

AA ADIPEX-P 37.5MG
LEMMON
AA DAPEX-37.5 37.5MG
FERNDAL LABS
AA PHENTERMINE HCL 37.5MG
CAMALL 16.75MG

PHENTOLAMINE HYDROCHLORIDE (PAGE 3-139)

/TABLET; ORAL/
/RESISTINE/
/CIBA/CIBA-BEIG/ /50MG/

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
(PAGE 3-140)

SYRUP; ORAL

PHENERGAN VC
MYETH LABS/AMHO 5MG/5ML;6.25MG/5ML

>_ADD> PIMOZIDE (PAGE 3-141)

>_ADD> TABLET; ORAL

>_ADD> ORAP
>_ADD> MCNEIL PHARM 2MG

>_ADD> POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM
>_ADD> BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
(PAGE 3-142)

>_ADD> POWDER FOR RECONSTITUTION; ORAL

>_ADD> GOLYTEL
>_ADD> BRAINTREE LABS 236GM/BOT;2.97GM/BOT;6.74GM/BOT;
>_ADD> 5.66GM/BOT;22.74GM/BOT

>_ADD> POTASSIUM ACETATE (PAGE 3-143)

>_ADD> INJECTABLE; INJECTION
>_ADD> POTASSIUM ACETATE IN PLASTIC CONTAINER
>_ADD> ABBOTT LABORATORIES 2MEQ/ML

POTASSIUM CHLORIDE (PAGE 3-143)

CAPSULE, CONTROLLED RELEASE; ORAL

MICRO-K 10
AH ROBINS 10MEQ

INJECTABLE; INJECTION

/AA/ POTASSIUM CHLORIDE /1MEQ/ML/
/AB/ TRAVENOL LABS /3MEQ/ML/
/AP/ /4MEQ/ML/

PREDNISOLONE (PAGE 3-145)

TABLET; ORAL

/BX/ PREDNISOLONE /5MG/
/BX/ /MYLAN PHARM/ /5MG/
/BX/ /REXALL DRUG/ /5MG/

PREDNISOLONE ACETATE (PAGE 3-146)

INJECTABLE; INJECTION

/BP/ PREDNISOLONE /25MG/ML/
/BP/ /FERNDAL LABS/

Digitized by Google

20

SECOBARBITAL SODIUM (PAGE 3-160)

CAPSULE; ORAL

<u>AA</u>	<u>SECCBARBITAL SODIUM</u>	<u>50MG</u>
	LANNETT	
<u>AA</u>	<u>SECONAL SODIUM</u>	<u>50MG</u>
<u>AA</u>	ELI LILLY	<u>100MG</u>

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
AT BAY LABORATORIES 2.5%

CREAM; TOPICAL
/SILVER SULFADIAZINE/
SSD

/SUSPENSION; ORAL/
/CYTELLIN/
/ELI LILLY/ /IGN/ISHL/

/POWDER, ORAL/
/CALCIBIND/
/MISSION PHARMACAL/ 12.5GM/PACKET/

INJECTABLE; INJECTION
SODIUM CHLORIDE IN PLASTIC CONTAINER
 > ADD >
 ABBOTT LABORATORIES 2.5HEQ/ML
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
 TRAVENOL LABS 3GM/100ML
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
 TRAVENOL LABS 5GM/100ML

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA ROXANE LABORATORIES 15GM/60ML*
SPS
AA CAROLINA MED PRODS 15GM/60ML

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
AB ROXANE LABORATORIES 324MG#

TABLET; ORAL
QUINIDINE SULFATE
> DLT > /AB/ /REXALL/ /200MG/
AB VITARINE/WEST CHEM 300MG

TABLET; ORAL
RAUWOLFIA SERPENTINA
/BP/ /KIRKMAN LABORATORIES/50MG/
/BP/ /100MG/

TABLET; ORAL	
/RAUWINE/	
/BP/	/ONEAL JONES/ELMAN/0.25MG
/RESERPINE	
/BP/	/BOLAR PHARMACEUTICAL/0.25MG
/BP/	/CORD LABORATORIES/0.1MG
/BP/	/0.5MG
/BP/	/MYLAN PHARMS 0.1MG
/BP/	/0.25MG
/RESINE/	
/BP/	/KIRKMAN LABORATORIES/0.1MG
/BP/	/0.25MG
/BP/	/0.5MG
/BP/	/1MG
/VIO-SERPINE/	
/BP/	/ROWELL LABORATORIES/0.1MG
/BP/	/0.25MG

Original from
UNIVERSITY OF MICHIGAN

THEOPHYLLINE (PAGE 3-176)

(FOR CONTROLLED RELEASE PRODUCTS - SEE SPECIAL NOTE C.)

CAPSULE, CONTROLLED RELEASE; ORAL

SOMOPHYLLIN-CRT

BC FISON 100MG

BC THEO-24

BC SEARLE/SEARLE PHARMS 100MGX

200MGX

300MGX

ELIXIR; ORAL

ELIXOHN

AA HR CENCI LABS 80MG/15MLX

SOLUTION; ORAL

THEOLAIR

AA RIKER LABS/3M 80MG/15ML

THEOPHYLLINE

AA ROXANE LABORATORIES 80MG/15MLX

TABLET, CONTROLLED RELEASE; ORAL

THEOCONTIN

BC PURDUE FREDERICK 200MGX

400MGX

THEO-DUR

BC KEY PHARMACEUTICALS 200MG

UNIPHYL

PURDUE FREDERICK 400MG

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL

THIORIDAZINE HCL

AA CORD LABORATORIES 80MG/MLX

AA 100MG/MLX

AA NATL PHARM MFG/BARRE 100MG/MLX

TABLET; ORAL

MELLARTIL

AB SANDOZ PHARMS/SANDOZ 100MG

AB 150MG

AB 200MG

THIORIDAZINE HCL

AB BARR LABORATORIES 10MGX

AB 15MGX

AB 25MGX

AB 50MGX

AB 100MGX

AB BOLAR PHARMACEUTICAL 10MGX

AB 100MGX

AB 150MGX

AB 200MGX

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

TABLET; ORAL

AB CHELSEA LABORATORIES 10MGX

AB 15MGX

AB 25MGX

AB 50MGX

AB 100MGX

AB CORD LABORATORIES 10MGX

AB 15MGX

AB 25MGX

AB 50MGX

AB DANBURY PHARMACAL 10MGX

AB 15MGX

AB 25MGX

AB 50MGX

> ADD > AB 100MGX

AB MYLAN PHARMS 100MGX

AB PAR PHARMACEUTICAL 10MGX

AB 15MGX

AB 25MGX

AB 50MGX

AB 100MGX

AB ROXANE LABORATORIES 10MGX

AB 15MGX

AB 25MGX

AB 50MGX

AB WEST-WARD 10MGX

AB 15MGX

AB 25MGX

AB 50MGX

AB ZENITH LABORATORIES 100MGX

TILOLOL MALEATE (PAGE 3-179)

TABLET; ORAL

BLOCADREN

MS&D/MERCK 5MG

TRIAMCINOLONE (PAGE 3-180)

TABLET; ORAL

TRIAMCINOLONE

/BP/ /BOLAR PHARMACEUTICAL/4MG/

/BP/ /MYLAN PHARMS/4MG/

/BP/ /BP/

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

AEROSOL; INHALATION

/ARISTOCORT/

/LEDERLE LABS/AM CYANO D. 25MG/INH/

AZMACORT

WILLIAM H RORER 0.25MG/INH

Original from
UNIVERSITY OF MICHIGAN

/AMINOPHYLLINE PHENOBARBITAL SODIUM HYDROCHLORIDE/
 (PAGE AD2)

/TABLET; ORAL/
 /AMPHROPH/ /100mg; 250mg/
 /SEARLE PHARMS/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
 ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE
 HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
 HYDROCHLORIDE; VITAMIN A; VITAMIN E (PAGE AD2)

INJECTABLE; INJECTION
 MVC PLUS
 ASCOT HOSP PHARMS 10MG/ML; 0.006MG/ML; 0.5 UG/M/ML;
 1.5MG/ML; 20 IU/ML; 0.04MG/ML;
 4MG/ML; 0.4MG/ML; 0.36MG/ML;
 0.3MG/ML; 330 IU/ML; 1 IU/ML

/BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE/
/PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/ELIXIR; ORAL/
 /ELIXIR, DINEETAP/ /4mg; 8mg; 12mg; 16mg; 20mg/
 /A.H. ROBINS/
 /TABLET; CONTROLLED RELEASE; ORAL/
 /DINEETAP/ /12mg; 16mg; 20mg/
 /A.H. ROBINS/

/CARBAMAZEPINE ENISTYLATE; CHLORPHENIRAMINE MALEATE; SODIUM PHOSPHATE/
/SODIUM PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/CAPSULE; CONTROLLED RELEASE; ORAL/
 /JUSS-ORIMADE/ /20mg; 40mg; 60mg; 80mg/
 /SK&F LABORATORIES/
 /SOLUTION; ORAL/
 /JUSS-ORIMADE/ /5mg; 10mg; 15mg; 20mg; 25mg; 30mg; 35mg; 40mg; 45mg; 50mg; 55mg; 60mg; 65mg; 70mg; 75mg; 80mg; 85mg; 90mg; 95mg; 100mg/
 /SK&F LABORATORIES/

> DLT > /DICYCLOHNE HYDROCHLORIDE/ (PAGE AD3)

(ALL PRODUCTS - SEE SPECIAL NOTE E.)

> DLT > /SYRUP; ORAL/
 > DLT > /BAYCLOHNE/
 > DLT > /BAY LABORATORIES/ /10mg; 25mg/

> DLT > /DICYCLOHNE HYDROCHLORIDE/ (PAGE AD3)

(ALL PRODUCTS - SEE SPECIAL NOTE E.)

> DLT > /TABLET; ORAL/
 > DLT > /DICYCLOHNE HCL/
 > DLT > /BARR LABORATORIES/ /20mg/

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL
 DIPYRIDAMOLE
 ASCOT HOSP PHARMS 50MG
 DURAMED PHARMS 25MG
 50MG
 75MG
 HALSEY DRUG 50MG
 SUPERPHARM 50MG
 WEST-WARD 25MG
 50MG
 75MG

ISOSORBIDE DINITRATE (PAGE AD5)

TABLET; ORAL
 ISOSORBIDE DINITRATE
 BARR LABORATORIES 30MG

TABLET; SUBLINGUAL
 ISOSORBIDE DINITRATE
 BARR LABORATORIES 10MG

TABLET, CONTROLLED RELEASE; ORAL
 ISOCHRON
 FOREST LABORATORIES 20MG

/METHAMPHOSTENOLONE/ (PAGE AD6)

/TABLET; ORAL/
 /METHAMPHOSTENOLONE/
 /PAR PHARMACEUTICAL/ /2.5mg/
 /5mg/

TABLETS, ORAL/
PARINATE/
SKF LABORATORIES/
EQ LONG BEACH/

TABLET, ORAL	/MINSTEROID/	/WINTHROP LABS/STERIL/2MG/
	/WINTHROP LABS/STERIL/2MG/	/WINTHROP LABS/STERIL/2MG/

CAPSULE, CONTROLLED RELEASE; ORAL
NITROGLYCERIN
CORD LABORATORIES
/VITARINE/NEST. CHEM/
/6.5mg/
/2.5mg/
VITARINE/PHOENIX
2.5MG
9.5MG
9MG

DESIST PENDING LIST - - EXEMPT. (COURT ORDER) CATEGORY
CUMULATIVE SUPPLEMENT NUMBER 10 / AUGUST, 83 - JULY, 84

CURRENT STATUS - PROBABLY EFFECTIVE

> DLT > /ANC/ /HERRELL'DON/DON CHEN/
> DLT > /ALLANTOIN; AMINACRINE HYDROCHLORIDE; SULFANILAMIDE/
(SEE SPECIAL NOTE E.)

CURRENT STATUS - INEFFECTIVE

/ACTIFED-C EXPECTORANT/ /BURROUGHS WELLCOME/
/CODEINE PHOSPHATE; GUAIFENESIN/
/PSEUDOPHEDRINE HYDROCHLORIDE; TRIPROLOLINE HYDROCHLORIDE/
/AMBENYL EXPECTORANT/ /HARION LABORATORIES/
/AMMONIUM CHLORIDE; BROMODIPHENHYDRAMINE HYDROCHLORIDE/
/CODEINE SULFATE; DIPHENHYDRAMINE HYDROCHLORIDE; MENTHOL/
/POTASSIUM GUAIACOSULFONATE/

AMODURINE SEARLE PHARMS
AMINOPHYLLINE; PHENOBARBITAL; RACEPHEDRINE HYDROCHLORIDE

> DLT > /AZO SANTANOL/ /HOFFMAN-LA ROCHE/
> DLT > /PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE/
(SEE SPECIAL NOTE E.)

/CARBITAL/ /PARKE-DAVIS/M-L/
/CARBONAL; PENTOBARBITAL SODIUM/

/CARTRAX-10/ /ROERIG/PIZIER/
/HYDROXYZINE HYDROCHLORIDE; PENTAERYTHRITOL TETRANITRATE/

/CARTRAX-20/ /ROERIG/PIZIER/
/HYDROXYZINE HYDROCHLORIDE; PENTAERYTHRITOL TETRANITRATE/

/CLISTIN BA/ /MCNEIL PHARM/
/CARBINOXAMINE MALEATE/

> DLT > /CORBRAN-N/ /ELI LILLY/
> DLT > /FLURANDRENOLIDE; NEOMYCIN SULFATE/
(SEE SPECIAL NOTE E.)

CORTISPORIN BURROUGHS WELLCOME
> DLT > /BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE/
> DLT > /POLYMYXIN B SULFATE/
(SEE SPECIAL NOTE E.)

/DIMEANE EXPECTORANT/ /AH ROBINS/
/BROMPHENIRAMINE MALEATE; GUAIFENESIN/
/PHENYLEPHRINE HYDROCHLORIDE/
/PHENYLPROPANOLAMINE HYDROCHLORIDE/

/DIMEANE EXPECTORANT-DC/ /AH ROBINS/
/BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; GUAIFENESIN/
/PHENYLEPHRINE HYDROCHLORIDE/
/PHENYLPROPANOLAMINE HYDROCHLORIDE/

CURRENT STATUS - INEFFECTIVE

/DIMEAPP/ /AH ROBINS/
/BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE/
/PHENYLPROPANOLAMINE HYDROCHLORIDE/

/ELIXIR DIMEAPP/ /AH ROBINS/
/BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE/
/PHENYLPROPANOLAMINE HYDROCHLORIDE/

/EQUAGESIC/ /WYETH LABS/AMH/
/ASPIRIN; ETHONEPTAZINE CITRATE; NEPROBANATE/

/EQUANITRATE-10/ /WYETH LABS/AMH/
/NEPROBANATE; PENTAERYTHRITOL TETRANITRATE/

/EQUANITRATE-20/ /WYETH LABS/AMH/
/NEPROBANATE; PENTAERYTHRITOL TETRANITRATE/

/FORNISTAL/ /CIBA/CIABA-GEIS/
/DIMEHINDENE MALEATE/

/GANTHRISIN/ /HOFFMAN-LA ROCHE/
/SULFISOXAZOLE/

/HYCODAPHEN/ /B' ASCHEN/
/ACETAMINOPHEN; HYDROCODONE BITARTRATE/

/ISOROL N/ /PHENOBARBITAL/ /IVES LABS/AMH/
/ISOBORBIDE DINITRATE; PHENOBARBITAL/

/KORO-SULF/ /HOLLAND-RANTOS/
/SULFISOXAZOLE/

METHANDROSTENOLONE PAR PHARMACEUTICAL
METHANDROSTENOLONE

> DLT > /NEO-CORT-DONE/ /HILES PHARMS/HILES/
> DLT > /HYDROCORTISONE; NEOMYCIN SULFATE/
(SEE SPECIAL NOTE E.)

> DLT > /NEO-CORTEF/ /UPJOHN/
> DLT > /HYDROCORTISONE ACETATE; NEOMYCIN SULFATE/
(SEE SPECIAL NOTE E.)

> DLT > /NEO-NEBROL ACETATE/ /UPJOHN/
> DLT > /METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE/
(SEE SPECIAL NOTE E.)

> DLT > /NEO-OXYLONE/ /UPJOHN/
> DLT > /FLUCORNEHOLONE; NEOMYCIN SULFATE/
(SEE SPECIAL NOTE E.)

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

[illegible]

CURRENT STATUS - INEFFECTIVE

[illegible]

D-SYNALAR/
/SYNTEX LABS/SYNTEX/
FLUOCINOLONE ACETONIDE, NEOHYDIN SULFATE/
(SEE SPECIAL NOTE E.)

> DLT > /NEOXYCIN SULFATE-HYDROCORTISONE ACETATE/
> DLT > /HYDROCORTISONE ACETATE, NEOXYCIN SULFATE/
(SEE SPECIAL NOTE E.)
/AMBI-X LABS/ORGANICS/

> DLT > /NEODECABRON/ /MSD/HERCK/
> DLT > /DEXAMETHASONE SODIUM PHOSPHATE/ NEOMYCIN SULFATE/ (SEE SPECIAL NOTE E.)

DESISTING LIST - OTHER THAN EXEMPT (COURT ORDER) CATEGORY
CUMULATIVE SUPPLEMENT NUMBER 11 / AUGUST '83 - JULY '84

SUBSCRIPTION FORM

APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
5TH EDITION (1984)

MAIL TO: _____ DATE: _____

Superintendent of Documents
Government Printing Office
Washington, DC 20402
(202) 783-3238

PURCHASER: _____ SHIP TO: _____
(If different than purchaser)

CONTACT: _____ TELEPHONE (Include Area Code) _____

METHOD OF PAYMENT

☐ Charge my GPO Account No. _____
☐ Purchase Order Number _____
☐ Check enclosed for \$ _____
 (Make check payable to Superintendent of Documents)

AUTHORIZING _____ DATE: _____
SIGNATURE

DESCRIPTION	QUANTITY	UNIT PRICE	TOTAL PRICE
The 5th Edition will be published in October, 1984. Subscription includes the Approved Prescription Drug Products List and monthly Cumulative Supplements.			
DOMESTIC		@ \$66.00	\$
FOREIGN		@ \$82.50	\$
ENTER TOTAL			\$

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

Digitized by **Google**

Original from
UNIVERSITY OF MICHIGAN

UNIVERSITY OF MICHIGAN



3 9015 07293 3164

Digitized by **Google**

Original from
UNIVERSITY OF MICHIGAN